ANTARES PHARMA, INC. (NASDAQ:ATRS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b)Effective March 1, 2019, Jacques Gonella, Ph.D., retired as a member of the Board of Directors (the “Board”) of Antares Pharma, Inc. (the “Company”). Dr. Gonella’s retirement from the Board is not a result of any dispute or disagreement with the Company.
(d) Upon the recommendation of the Board’s Governance and Nominating Committee, the Board appointed Karen L. Smith, M.D., Ph.D., M.B.A., LL.M., to the Board as a Class III Director effective as of March 1, 2019 to fill the vacancy on the Board created by Dr. Gonella’s retirement. Dr. Smith’s term will expire at the Company’s 2019 Annual Meeting of Stockholders.
Dr. Smith will be compensated to the Company’s non-employee director compensation plan as disclosed in the Company’s Proxy Statement on Schedule 14A for the 2018 Annual Meeting of Stockholders (the “Proxy Statement”) including, without limitation, an initial grant of options to purchase 20,000 shares of the Company’s common stock at an exercise price per share that is equal to the closing price per share of the Company’s common stock on the date of the grant.Dr. Smith also will enter into an indemnification agreement with the Company substantially in the form used for other directors as disclosed in the Proxy Statement.
There is no arrangement or understanding between Dr. Smith and any other persons to which Dr. Smith was appointed to serve as a director of the Company.There are no relationships between Dr. Smith and the Company that would require disclosure to Item 404(a) of Regulation S-K.
Item 5.02 Regulation FD Disclosure.
A copy of the Company’s press release announcing the retirement of Dr. Gonella from the Board and the appointment of Dr.Smith to the Board is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 5.02 by reference.
The information disclosed under this Item 5.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
|
Item 5.02 |
Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated March 4, 201/p> |
ANTARES PHARMA, INC. Exhibit
EX-99.1 2 atrs-ex991_7.htm EX-99.1 atrs-ex991_7.htm EXHIBIT 99.1 NEWS RELEASE ANTARES PHARMA APPOINTS DR. KAREN SMITH TO BOARD OF DIRECTORS AND ANNOUNCES RETIREMENT OF DR. JACQUES GONELLA EWING,…
To view the full exhibit click here
About ANTARES PHARMA, INC. (NASDAQ:ATRS)
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.